These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34311086)

  • 1. Chemical update on the potential for serotonin 5-HT
    Kucwaj-Brysz K; Baltrukevich H; Czarnota K; Handzlik J
    Bioorg Med Chem Lett; 2021 Oct; 49():128275. PubMed ID: 34311086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Top Med Chem; 2008; 8(12):1035-48. PubMed ID: 18691131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B; Martín-Fontecha M; Vázquez-Villa H; Pardo L; López-Rodríguez ML
    J Med Chem; 2014 Sep; 57(17):7160-81. PubMed ID: 24850589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and Therapeutic Potential of the 5-HT
    Blattner KM; Canney DJ; Pippin DA; Blass BE
    ACS Chem Neurosci; 2019 Jan; 10(1):89-119. PubMed ID: 30020772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 5-HT
    Ferrero H; Solas M; Francis PT; Ramirez MJ
    CNS Drugs; 2017 Jan; 31(1):19-32. PubMed ID: 27914038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of 5-HT6 Receptor Agonists.
    Karila D; Freret T; Bouet V; Boulouard M; Dallemagne P; Rochais C
    J Med Chem; 2015 Oct; 58(20):7901-12. PubMed ID: 26099069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.
    Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P
    Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update.
    Khoury R; Grysman N; Gold J; Patel K; Grossberg GT
    Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.
    Ivachtchenko AV; Okun I; Aladinskiy V; Ivanenkov Y; Koryakova A; Karapetyan R; Mitkin O; Salimov R; Ivashchenko A
    J Alzheimers Dis; 2017; 58(4):1043-1063. PubMed ID: 28550249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin: A New Hope in Alzheimer's Disease?
    Claeysen S; Bockaert J; Giannoni P
    ACS Chem Neurosci; 2015 Jul; 6(7):940-3. PubMed ID: 26011650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating 5-HT
    Lalut J; Karila D; Dallemagne P; Rochais C
    Future Med Chem; 2017 May; 9(8):781-795. PubMed ID: 28504917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.
    Grychowska K; Satała G; Kos T; Partyka A; Colacino E; Chaumont-Dubel S; Bantreil X; Wesołowska A; Pawłowski M; Martinez J; Marin P; Subra G; Bojarski AJ; Lamaty F; Popik P; Zajdel P
    ACS Chem Neurosci; 2016 Jul; 7(7):972-83. PubMed ID: 27100049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylpiperazine derivatives acting at 5-HT(1A) receptors.
    López-Rodríguez ML; Ayala D; Benhamú B; Morcillo MJ; Viso A
    Curr Med Chem; 2002 Feb; 9(4):443-69. PubMed ID: 11945120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.
    Nikiforuk A
    Rev Neurosci; 2014; 25(3):367-82. PubMed ID: 24501158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
    Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
    Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.
    Millan MJ; Dekeyne A; Gobert A; Brocco M; Mannoury la Cour C; Ortuno JC; Watson D; Fone KCF
    Neuropharmacology; 2020 Oct; 177():108099. PubMed ID: 32525060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-hydroxytryptamine (5-HT) receptor ligands.
    Kitson SL
    Curr Pharm Des; 2007; 13(25):2621-37. PubMed ID: 17897004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K; Haupt A; Bespalov A
    Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multitargeting the Action of 5-HT
    Czarnota-Łydka K; Kucwaj-Brysz K; Pyka P; Haberek W; Podlewska S; Handzlik J
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models.
    Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM
    Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.